All currently available GLP-1 medications carry the same boxed warning regarding thyroid C-cell tumors based on animal studies, and none have demonstrated superiority or increased risk specifically in patients with autoimmune thyroid disease
Identifying GLP-1 Non-Responders Early in Treatment Early identification of patients who may not respond adequately to GLP-1 receptor agonist therapy represents a critical step in optimizing obesity treatment pathways
B., Secher, A., Hecksher-Srensen, J
Crohns Colitis 15 , 20882102 (2021)
Furthermore, it was reported that therapy with GLP-1 enhanced epithelial architecture, lowered the assembly of pro-inflammatory cytokines like TGF, and dramatically delayed the emergence of DSS-induced colitis
Those with pre-existing mental health conditions may require closer monitoring and coordinated care between GP, diabetes specialists, and mental health professionals